- Dr. Malcolm Ross
- Generapharm, Switzerland
Dr. Ross has over 30 years experience in the Generics Industry, the last 15 being at corporate level. He has been intimately involved in strategic planning, pipeline management and related activities. His early industrial experience with Teva and Taro were directed primarily to the US markets but later as President of IPR, a company jointly owned by PAR and Merck Generics followed by R&D director for Polpharma, his role expanded to include development for the European markets. Technically Malcolm specializes in development, both of formulations and analytical methodologies and holds a number of patents for novel formulations. He has set up R&D departments from scratch and has been responsible for upgrading existing units to European standards. Experienced in GMP and QA issues Malcolm has carried out many audits worldwide, both for API and Finished dosage forms. In 2006 Malcolm moved to Basel and established Generapharm, a training and consultancy company.
- Peter Wittner
- Senior Consultant
- Interpharm Consultancy, United Kingdom
Peter Wittner, B.Sc., is an independent consultant specialising in the commercial aspects of generics with more than 40 years’ pharmaceutical experience. The major part of this has been spent the generic industry. He was Managing Director for the UK subsidiary of the Indian generic leader Ranbaxy, having joined them to set up the business before returning to consultancy work. Before that, he had headed the European Sales & Marketing department of the UK generics companies Evans Medical and H.N. Norton, which later became part of IVAX and then Teva.
In the field of generics, Interpharm works with new market entrants on developing commercial strategies, compiling competitor intelligence and gaining EU- GMP approval and assists in business development for companies that are trying to enter the market. Recently, he has become increasingly involved in the field of biosimilars. On the other side of the equation, Interpharm has also worked with originator companies that are looking at ways of defending their major brands from generic incursion or themselves considering entry in to the field of generics. Peter is a regular speaker at generic conferences, and runs workshops on generics and Biosimilars topics for a number of organisations as well as conducting training seminars.